Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Cytokinetics, Incorporated

announced today that two posters are scheduled to be presented at the 22nd International Symposium on ALS/MND to be held November 30, 2011 - December 2, 2011 at the Hilton Sydney in Sydney, Australia. One poster will present data from the first cohort, or Part A, of an ongoing Phase II clinical trial evaluating multiple fixed doses of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS) who are not receiving riluzole. The other poster will review the history of the ALS Functional Rating Scale - Revised (ALSFRS-R). CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue. CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program.